HIGHLIGHTS Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care ...
Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial ...
Class 10 results declared, pass percentage awaited, link at bseodisha.nic.in. The online marksheet link will be available ...
Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemotherapy Ovarian cancer represents a major target ...
Today's applications require monitoring, logging, configuration, etc. Each of these concerns can be implemented as a ...
Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.
Detailed price information for Adyton Resources Corporation (ADY-X) from The Globe and Mail including charting and trades.
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and ...
Family offices are tapping wealth management firms and OCIOs to increase tax efficiency in their portfolios. U.S. listed ETFs ...
MedPage Today on MSN
No Survival Benefit With Mastectomy in Younger, High-Risk Breast Cancer
Higher tumor grade, more residual tumor after neoadjuvant therapy were only significant fa ...
Neil Mellor praised one Liverpool player for a ‘standout performance’ in the 3-2 defeat to Manchester United on ...
Majors are spending record sums to squeeze extra life out of aging mines while the discovery pipeline quietly drains. That ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results